Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Japan’s sovereign development bank is investing in UK life sciences for the first time with funding for 4Bio Capital, a UK venture fund that backs advanced treatments such as cell and gene therapies....
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...[Enlarge] Further reading:— Alert: Alphaville LLC issues new research report on Duchy of Cornwall (FTAV)— Greenland: Alphaville put on its sellside hat for the deal of the century (FTAV)— Alphaville LLC...
...Claire Kumar Senior Research Fellow, ODI (Formerly Overseas Development Institute), Bangor, County Down, UK...
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...There is a lot of data on profitable and hotly pursued research fields like cancer, for example. There is less on relatively neglected areas such as mental health or infectious diseases....
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...It has 178 prospects at various stages of development; it has been striking a series of deals, including last month’s $2.4bn agreement to buy Canadian biotech Fusion Pharmaceuticals aimed at bolstering its...
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...Treatments like this come with large upfront research and development costs but, by preventing chronic diseases, could lead to long-term savings: the yearly costs of asthma in the US alone are $56bn, mainly...
...This meant a significant proportion of cancer research was only possible because of public donations, she added....
...Pointing to the risks of unnecessary treatment, Cancer Research UK said over-diagnosis could have “a negative psychological impact”, and treatment of prostate cancer could also cause physical side effects...
...One of his most well-known contributions to research is the ‘Sally-Anne task’....
...“They end up being clustered around genes that are altered in cancer in a variety of different ways, providing the first glimpse that these sequences may be key to tumour development,” he said....
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...Gathering more than 600 studies in development economics, she found less than 10 per cent mentioned a policy’s costs. (Policymakers care about prices.)...
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Johnson’s team have said he had acted as a “diplomatic back channel for the UK”, but the Foreign, Commonwealth and Development Office said he was “not acting on behalf of the UK government”....
...However, even more interesting (and counter-intuitive) is Rogoff et al’s failure to find a statistical correlation between real rates and fundamental economic trends....
International Edition